Cancer: More than a geneticist's Pandora's box

Area of Science:

• Oncology
• Systems Biology
• Genetics

Background:

• Cancer cell populations exhibit phenotypic variations despite identical genetic makeup, known as nongenetic or non-mutational heterogeneity.
• This heterogeneity is a fundamental aspect of biological systems and is linked to critical cancer progression factors like metastasis, therapy resistance, and tumor relapse.

Purpose of the Study:

• To review the evidence for the existence, sources, and implications of non-genetic heterogeneity across various cancer types.
• To explore the role of phenotypic plasticity in adaptive drug resistance and metastatic fitness.

Main Methods:

• Review of existing evidence on non-genetic heterogeneity in cancer.
• Discussion of potential sources including transcriptional stochasticity, protein conformation, and microenvironmental factors.
• Highlighting the utility of computational and mathematical modeling alongside in vitro/in vivo experiments.

Main Results:

• Non-genetic heterogeneity arises from sources like transcriptional noise, protein conformation changes, and the microenvironment.
• Phenotypic plasticity, enabled by gene regulatory network dynamics, allows reversible cell-state transitions.
• This plasticity contributes to adaptive drug resistance and enhanced metastatic potential.

Conclusions:

• Non-genetic heterogeneity is a key driver of cancer progression and treatment failure.
• Understanding phenotypic plasticity is crucial for developing effective cancer therapies.
• A systems-level approach integrating mathematical modeling and experimental data is essential to map cancer's phenotypic diversity and identify therapeutic vulnerabilities.